You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Inflammatory Diseases
Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial
30 June 2020 - - US-based biotechnology company NuvOx Pharma, which is developing NanO2 emulsion for oxygen delivery, has received a "No Objection Letter" from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure, the company said.
Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome.
ARDS, which is associated with lung inflammation leading to low blood oxygenation, is the major cause of death in COVID-19 patients.
The trial will determine if NanO2 improves clinical outcomes in COVID-19 subjects with acute hypoxic respiratory failure. NanO2 has the potential to transform the care of COVID-19 patients who present with low oxygen saturation.
Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome.
ARDS, which is associated with lung inflammation leading to low blood oxygenation, is the major cause of death in COVID-19 patients.
The trial will determine if NanO2 improves clinical outcomes in COVID-19 subjects with acute hypoxic respiratory failure. NanO2 has the potential to transform the care of COVID-19 patients who present with low oxygen saturation.
Login
Related Headlines
Allergan and Molecular Partners receive FDA response regarding Abicipar pegol for neovascular AMD
Noxopharm Starts COVID-19 Trial Programme in Europe
Moderna and Catalent Team for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate